Knick-knack PADIMAC

Abstract

In this issue of Blood, Chapman et al1 have derived a 7-gene expression signature that predicts whether a newly diagnosed myeloma patient will respond to treatment with bortezomib when autologous stem cell transplant (ASCT) is not considered as part of the upfront therapy.